Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 43 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Tourmaline Bio Inc | TRML | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 13.55 | 09:29:36 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 13.55 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 10 | 43 | - | 9.18 - 48.31 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 08:56:18 | 15 | $ 14.22 | USD |
Tourmaline Bio Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 276.58M | 20.34M | - | 0 | -42.12M | -2.07 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Tourmaline Bio News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical TRML Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 13.63 | 14.26 | 13.185 | 13.60 | 329,509 | -0.08 | -0.59% |
| 1 Month | 15.53 | 15.97 | 13.16 | 14.24 | 266,553 | -1.98 | -12.75% |
| 3 Months | 42.16 | 48.31 | 13.16 | 21.58 | 463,991 | -28.61 | -67.86% |
| 6 Months | 19.76 | 48.31 | 13.16 | 25.41 | 332,024 | -6.21 | -31.43% |
| 1 Year | 10.32 | 48.31 | 9.18 | 24.94 | 280,607 | 3.23 | 31.30% |
| 3 Years | 10.32 | 48.31 | 9.18 | 24.94 | 280,607 | 3.23 | 31.30% |
| 5 Years | 10.32 | 48.31 | 9.18 | 24.94 | 280,607 | 3.23 | 31.30% |
Tourmaline Bio Description
| Talaris Therapeutics Inc is a late-clinical stage biotechnology company. It is developing transformative cell therapies with the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients as well as induce durable remissions in patients with severe autoimmune and immune-mediated disorders. |
